Kexing Biopharm, a Chinese biopharmaceutical company headquartered in Shangdong Province, developed a COVID-19 vaccine, CoronaVac. Brazil has been conducting stage 3 testing of this vaccine. It recently reported that the vaccine’s effective rate was 50.38 percent. The two vaccines of the U.S. Company Pfizer had a 95 percent efficacy rate and Moderna had a 94.1 percent rate.
China’s vaccine passed the 50 percent mark that World Health Organization set. However, its low efficacy rate impacted Beijing’s bid to use the vaccine to boost its international influence.
Over ten countries have pre-ordered 380 million of China’s CoronaVac vaccine.
Excerpt in Chinese:
巴西圣保罗布坦坦周二宣称，由中国科兴开发的克尔来福（CoronaVac）冠状病毒病疫苗，根据最新测试结果显示有效率只五成以上，比起早前的测试有效率78%下跌几乎30个百分点，仅仅达到世卫标准，纽约时报形容，这个测试结果对企图以疫苗达到外交目的的中国，影响至巨。报道指全球至少已有10个国家预购超过3.8亿剂科兴研发的药苗。
Source: Radio France International, January 14, 2021
https://www.rfi.fr/cn/中国/20210114-有效率只五成科兴还称疫苗良好100万剂下月抵港